BidaskClub upgraded shares of InVitae Corp (NASDAQ:NVTA) from a sell rating to a hold rating in a research report sent to investors on Tuesday.

NVTA has been the subject of a number of other reports. Zacks Investment Research raised shares of InVitae Corp from a sell rating to a hold rating in a report on Friday, August 11th. J P Morgan Chase & Co reaffirmed an overweight rating and issued a $15.00 target price (up from $14.00) on shares of InVitae Corp in a report on Wednesday, August 9th. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus target price of $14.33.

InVitae Corp (NASDAQ NVTA) opened at 9.89 on Tuesday. The firm’s market capitalization is $430.65 million. The company has a 50 day moving average price of $9.31 and a 200 day moving average price of $9.31. InVitae Corp has a 52-week low of $5.76 and a 52-week high of $10.96.

InVitae Corp (NASDAQ:NVTA) last announced its quarterly earnings results on Monday, August 7th. The medical research company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.02). InVitae Corp had a negative net margin of 199.20% and a negative return on equity of 153.27%. The company had revenue of $14.34 million during the quarter, compared to analysts’ expectations of $13.31 million. During the same period last year, the firm earned ($0.77) earnings per share. InVitae Corp’s revenue was up 157.0% on a year-over-year basis. On average, equities analysts forecast that InVitae Corp will post ($2.35) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “InVitae Corp (NVTA) Upgraded to Hold by BidaskClub” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/invitae-corp-nvta-upgraded-to-hold-by-bidaskclub/1614432.html.

Several large investors have recently made changes to their positions in the company. California State Teachers Retirement System raised its holdings in shares of InVitae Corp by 24.1% in the second quarter. California State Teachers Retirement System now owns 69,009 shares of the medical research company’s stock valued at $660,000 after buying an additional 13,400 shares during the last quarter. The Manufacturers Life Insurance Company raised its holdings in shares of InVitae Corp by 34.5% in the second quarter. The Manufacturers Life Insurance Company now owns 32,129 shares of the medical research company’s stock valued at $307,000 after buying an additional 8,244 shares during the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of InVitae Corp in the second quarter valued at about $202,000. State Street Corp raised its holdings in shares of InVitae Corp by 43.1% in the second quarter. State Street Corp now owns 577,978 shares of the medical research company’s stock valued at $5,528,000 after buying an additional 174,016 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in shares of InVitae Corp by 131.3% in the second quarter. Royal Bank of Canada now owns 126,631 shares of the medical research company’s stock valued at $1,210,000 after buying an additional 71,892 shares during the last quarter.

About InVitae Corp

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients.

Receive News & Ratings for InVitae Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InVitae Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.